We canβt show the full text here under this license. Use the link below to read it at the source.
Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials
Effects and safety of GLP-1 receptor drugs on weight and metabolism in women with PCOS
AI simplified
Abstract
GLP-1 receptor agonists significantly reduced body mass index, body weight, waist circumference, waist-to-hip ratio, and abdominal girth in women with polycystic ovary syndrome (P < 0.0001).
- GLP-1 receptor agonists led to significant reductions in fasting insulin and glucose levels at 2 hours after an oral glucose tolerance test.
- A decrease in insulin resistance, as measured by HOMA-IR, was observed with GLP-1 receptor agonist treatment.
- No significant changes were noted in hormone levels or lipid profiles, except for a reduction in HDL cholesterol.
- Treatment with GLP-1 receptor agonists was associated with increased reports of nausea, vomiting, and dizziness.
- Further research is necessary to assess the long-term effects of GLP-1 receptor agonists on glucose homeostasis and lipid profiles.
AI simplified
Key numbers
1.59
Reduction
Mean difference in compared to metformin or placebo.
3.57 kg
Body Weight Reduction
Mean difference in body weight compared to metformin or placebo.
3.07
Increase in Nausea Events
Odds ratio for nausea compared to metformin or placebo.